Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00255060|
Recruitment Status : Completed
First Posted : November 17, 2005
Last Update Posted : July 20, 2010
|Condition or disease|
General Purpose: The purpose of our protocol is develop a comprehensive screening protocol for women at high risk for developing breast cancer in the hopes of detecting breast cancer or it's precursor lesions at the earliest possible stage and reducing breast cancer mortality.
The following are our specific goals in this endeavor;
- To assess the sensitivity and specificity of MRI in breast cancer detection in women at high risk compared to mammography
- To assess the ability of random periareolar fine needle aspiration to detect abnormal ductal cells and to correlate these results with MRI and mammogram findings
- To assess appropriate screening intervals for BRCA1/2 mutation carriers and women with a >10% risk of developing breast cancer in ten years The following aims will be outlined in detail under methodology.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer|
|Study Start Date :||November 2001|
|Actual Primary Completion Date :||July 2006|
|Actual Study Completion Date :||June 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00255060
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||James M Ford||Stanford University|